AMAG Pharmaceuticals (AMAG) Earning Somewhat Favorable Media Coverage, Accern Reports
News articles about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.6705383253577 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- B. Riley Begins Coverage on AMAG Pharmaceuticals (AMAG) (americanbankingnews.com)
- Contrast Media Market to Enlist Popularity rate at ~6.3% of CAGR by 2023 (medgadget.com)
- Intravenous Iron Drugs Market – Preventive Methods and Market Trends 2017 – 2025 (sbwire.com)
- What will the Global Nanomedicine Market size and the growth rate be in 2022? (medgadget.com)
- $163.39 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter (americanbankingnews.com)
A number of research firms have recently commented on AMAG. B. Riley began coverage on AMAG Pharmaceuticals in a report on Thursday. They set a “neutral” rating and a $16.00 price target for the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Jefferies Group reaffirmed a “buy” rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Morgan Stanley lowered their target price on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Finally, Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $23.38.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.15 during midday trading on Friday, hitting $14.10. The company’s stock had a trading volume of 664,700 shares, compared to its average volume of 1,092,308. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $36.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.